Skip to main content
Top
Published in: Diabetologia 11/2010

01-11-2010 | Commentary

Ageing brain abnormalities in young obese patients with type 2 diabetes: a cause for concern

Author: J. J. Nolan

Published in: Diabetologia | Issue 11/2010

Login to get access

Excerpt

Early onset type 2 diabetes is increasing in prevalence, in parallel with the worldwide obesity epidemic [1], and is typically characterised by early onset obesity and severe insulin resistance in young people with a strong family history of type 2 diabetes [1, 2]. Young patients with type 2 diabetes have been shown to have higher rates of hypertension and microalbuminuria than age-matched peers who have type 1 diabetes, despite better metabolic control and a shorter duration of diabetes [3]. We and others have shown that young obese patients with this phenotype are severely insulin resistant (even when compared with equally obese non-diabetic peers of similar age) and have a characteristic dyslipidaemia, with low HDL-cholesterol and elevated fasting triacylglycerol [2, 4]. It has recently been shown that young type 2 diabetic patients also have blunted or absent metabolic and fitness responses to aerobic exercise training, associated with abnormalities in key muscle mitochondrial regulatory responses to exercise [4, 5]. Given the early onset of diabetes in these young individuals, the marked distinctions between their phenotype and that of typical type 1 diabetes and the potentially long subsequent duration of disease, the most important clinical question, unanswered up to now, has been whether this early onset form of type 2 diabetes will lead to more serious end-organ complications. …
Literature
1.
go back to reference Fagot-Campagna A, Pettitt DJ, Engelgau MM et al (2000) Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 136:664–672CrossRefPubMed Fagot-Campagna A, Pettitt DJ, Engelgau MM et al (2000) Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 136:664–672CrossRefPubMed
2.
go back to reference McQuaid S, O’Gorman DJ, Yousif O et al (2005) Early-onset insulin-resistant diabetes in obese Caucasians has features of typical type 2 diabetes, but 3 decades earlier. Diabetes Care 28:1216–1218CrossRefPubMed McQuaid S, O’Gorman DJ, Yousif O et al (2005) Early-onset insulin-resistant diabetes in obese Caucasians has features of typical type 2 diabetes, but 3 decades earlier. Diabetes Care 28:1216–1218CrossRefPubMed
3.
go back to reference Eppens MC, Craig ME, Cusumano J et al (2006) Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 29:1300–1306CrossRefPubMed Eppens MC, Craig ME, Cusumano J et al (2006) Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 29:1300–1306CrossRefPubMed
4.
go back to reference Burns N, Finucane FM, Hatunic M et al (2007) Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia 50:1500–1508CrossRefPubMed Burns N, Finucane FM, Hatunic M et al (2007) Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia 50:1500–1508CrossRefPubMed
5.
go back to reference Hernández MI, Thabit H, Burns N et al (2010) Subjects with early-onset type 2 diabetes show defective activation of the skeletal muscle PGC-1α/mitofusin-2 regulatory pathway in response to physical activity. Diabetes Care 33:645–651CrossRef Hernández MI, Thabit H, Burns N et al (2010) Subjects with early-onset type 2 diabetes show defective activation of the skeletal muscle PGC-1α/mitofusin-2 regulatory pathway in response to physical activity. Diabetes Care 33:645–651CrossRef
6.
go back to reference Yau PL, Javier DC, Ryan CM et al. (2010) Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus. Diabetologia. doi:10.1007/s00125-010-1857-y Yau PL, Javier DC, Ryan CM et al. (2010) Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus. Diabetologia. doi:10.​1007/​s00125-010-1857-y
7.
go back to reference Manschot SM, Brands AMA, van der Grond J et al (2006) Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55:1106–1113CrossRefPubMed Manschot SM, Brands AMA, van der Grond J et al (2006) Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55:1106–1113CrossRefPubMed
8.
go back to reference van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ (2007) Brain imaging in patients with diabetes: a systematic review. Diabetes Care 29:2539–2548CrossRef van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ (2007) Brain imaging in patients with diabetes: a systematic review. Diabetes Care 29:2539–2548CrossRef
Metadata
Title
Ageing brain abnormalities in young obese patients with type 2 diabetes: a cause for concern
Author
J. J. Nolan
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1890-x

Other articles of this Issue 11/2010

Diabetologia 11/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine